Glenmark Pharmaceuticals Ltd. said its subsidiary Glenmark Generics Inc. USA, commenced marketing and distribution of Levetiracetam 250mg, 500mg and 750 mg tables in the US market from January 16.

Levetiracetam tables are used as an adjunctive therapy for treatment of partial onset seizures in adults and children (above 4 years) with epilepsy.

As per IMS Health data, as at the end of September 2008 the tablets recorded sales of $1.1 billion, up 36% over the corresponding period for the previous year.

The Mumbai-based company has already entered into a longstanding partnership with US-based Invagen Pharmaceuticals Inc., to promote the product. As per agreement, Glenmark will exclusively market and distribute the product, while Invagen will be responsible for the manufacture and supply.

With this approval, Glenmark will now have 38 generic products authorized for distribution in the US market, the company said.